
Novavax, Inc. (NASDAQ:NVAX) shares slumped 22.27% after-hours on Monday, reacting to its quarterly financial report. What would have been a trophy quarter to flaunt, given COVID-19 revenue only just began to trickle in, turned out to be a big disappointment.
Here're five reasons why the COVID-19 vaccine maker's report triggered a negative reaction: